Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.13
CUR's Cash to Debt is ranked higher than
64% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. CUR: 3.13 )
CUR' s 10-Year Cash to Debt Range
Min: 0.22   Max: No Debt
Current: 3.13

Equity to Asset 0.59
CUR's Equity to Asset is ranked higher than
68% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CUR: 0.59 )
CUR' s 10-Year Equity to Asset Range
Min: -8.17   Max: 0.87
Current: 0.59

-8.17
0.87
F-Score: 4
Z-Score: 0.49
M-Score: 115.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -91768.42
CUR's Operating margin (%) is ranked lower than
52% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. CUR: -91768.42 )
CUR' s 10-Year Operating margin (%) Range
Min: -91768.42   Max: -507.12
Current: -91768.42

-91768.42
-507.12
Net-margin (%) -119094.74
CUR's Net-margin (%) is ranked lower than
52% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. CUR: -119094.74 )
CUR' s 10-Year Net-margin (%) Range
Min: -119100   Max: -534.63
Current: -119094.74

-119100
-534.63
ROE (%) -115.49
CUR's ROE (%) is ranked higher than
57% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. CUR: -115.49 )
CUR' s 10-Year ROE (%) Range
Min: -1295.32   Max: -147.69
Current: -115.49

-1295.32
-147.69
ROA (%) -76.83
CUR's ROA (%) is ranked higher than
58% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. CUR: -76.83 )
CUR' s 10-Year ROA (%) Range
Min: -481.63   Max: -91.88
Current: -76.83

-481.63
-91.88
ROC (Joel Greenblatt) (%) -6000.00
CUR's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. CUR: -6000.00 )
CUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10806.9   Max: -3891.19
Current: -6000

-10806.9
-3891.19
Revenue Growth (3Y)(%) -100.00
CUR's Revenue Growth (3Y)(%) is ranked higher than
56% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. CUR: -100.00 )
CUR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 26
Current: -100

0
26
EBITDA Growth (3Y)(%) -2.60
CUR's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. CUR: -2.60 )
CUR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.2   Max: 35.7
Current: -2.6

-17.2
35.7
» CUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CUR Guru Trades in

Q1 2014

CUR Guru Trades in Q1 2014

George Soros 191,600 sh (New)
» More
Q2 2014

CUR Guru Trades in Q2 2014

Paul Tudor Jones 12,120 sh (New)
George Soros Sold Out
» More
Q3 2014

CUR Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.70
CUR's P/B is ranked higher than
56% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. CUR: 9.70 )
CUR' s 10-Year P/B Range
Min: 3.74   Max: 64
Current: 9.7

3.74
64
P/S 8924.50
CUR's P/S is ranked lower than
53% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. CUR: 8924.50 )
CUR' s 10-Year P/S Range
Min: 0   Max: 451
Current: 8924.5

0
451
EV-to-EBIT -9.27
CUR's EV-to-EBIT is ranked higher than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CUR: -9.27 )
CUR' s 10-Year EV-to-EBIT Range
Min: -26.9   Max: -2.1
Current: -9.27

-26.9
-2.1
Current Ratio 7.02
CUR's Current Ratio is ranked higher than
82% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CUR: 7.02 )
CUR' s 10-Year Current Ratio Range
Min: 0.04   Max: 7.41
Current: 7.02

0.04
7.41
Quick Ratio 7.02
CUR's Quick Ratio is ranked higher than
83% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CUR: 7.02 )
CUR' s 10-Year Quick Ratio Range
Min: 0.04   Max: 7.41
Current: 7.02

0.04
7.41
Days Sales Outstanding 4.00
CUR's Days Sales Outstanding is ranked higher than
98% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. CUR: 4.00 )
CUR' s 10-Year Days Sales Outstanding Range
Min: 2.68   Max: 4341.58
Current: 4

2.68
4341.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.80
CUR's Price/Net Cash is ranked higher than
77% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. CUR: 10.80 )
CUR' s 10-Year Price/Net Cash Range
Min: 13.63   Max: 60
Current: 10.8

13.63
60
Price/Net Current Asset Value 10.80
CUR's Price/Net Current Asset Value is ranked higher than
74% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. CUR: 10.80 )
CUR' s 10-Year Price/Net Current Asset Value Range
Min: 12.11   Max: 96.5
Current: 10.8

12.11
96.5
Price/Tangible Book 10.30
CUR's Price/Tangible Book is ranked higher than
62% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. CUR: 10.30 )
CUR' s 10-Year Price/Tangible Book Range
Min: 7.4   Max: 60
Current: 10.3

7.4
60
Earnings Yield (Greenblatt) -11.20
CUR's Earnings Yield (Greenblatt) is ranked higher than
64% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CUR: -11.20 )
CUR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11.1   Max: 0
Current: -11.2

-11.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7NS.Germany,
Neuralstem, Inc. was incorporated in 1996 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is engaged in development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative conditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company's competitors include multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.
» More Articles for CUR

Headlines

Articles On GuruFocus.com
Neuralstem Inc. Reports Operating Results (10-Q) Nov 15 2010 
View on CUR Sep 12 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 16 2010 
Neuralstem Inc. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buys Highlight: Neuralstem Inc., Converted Organics Inc., Princeton National Bancorp Inc. Jan 10 2010 
Weekly CEO Buy Highlights: Helix Energy Solutions Group Inc, Neuralstem Inc, Saul Centers Inc, Casua Jan 09 2010 
Weekly CFO Buy Highlights: Neuralstem Inc., New Generation Biofuels Holdings, Converted Organics, Or Jan 05 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Nov 16 2009 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 15 2009 

More From Other Websites
Neuralstem To Present At Barclays Global Healthcare Conference 2015 Mar 23 2015
Neuralstem Announces Topline Results Of Phase II ALS Trial Mar 23 2015
NEURALSTEM, INC. Financials Mar 21 2015
CUR: Quick Analysis Of Neuralstem's Phase 2a ALS Data Mar 17 2015
NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 16 2015
Neuralstem Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results Mar 16 2015
NEURALSTEM, INC. Files SEC form 10-K, Annual Report Mar 16 2015
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin Mar 13 2015
NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements... Mar 12 2015
Neuralstem Stock Plunges After Latest Study on ALS Drug Mar 12 2015
Neuralstem Announces Topline Results Of Phase II ALS Trial Mar 12 2015
Neuralstem To Present At Barclays Global Healthcare Conference 2015 Mar 04 2015
NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Mar 02 2015
CTT SYSTEMS receives first airline order for A350-900 humidifiers Feb 25 2015
Coverage initiated on Neuralstem by Brean Capital Feb 18 2015
NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Feb 09 2015
CTT Systems receives order on Zonal Drying™ for six Boeing 737-800s Feb 05 2015
Neuralstem to Present at BIO CEO & Investor Conference 2015 Feb 03 2015
Neuralstem To Present At Biotech Showcase 2015 Jan 06 2015
Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars Jan 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK